Novo Nordisk Expects to Hire 6,000 Employees by 2022
News Jun 11, 2014
The new jobs will have the derived effect of boosting employment by more than 15,000 jobs nationally.
This is revealed by a new analysis to be presented by Novo Nordisk today at the ‘Invitation to growth – a road to job creation’ conference. The analysis homes in on the value created in the interaction between growth businesses and public-sector research and education, as well as the challenges that must be solved so that research-based businesses can continue to grow in Denmark.
"With the expectation of creating 6,000 new jobs in Denmark over the coming years, it will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent," says Executive Vice President and Chief Science Officer Mads Krogsgaard Thomsen.
The analysis presents new forecasts for the future availability of university graduates and PhDs and questions whether Denmark is investing sufficiently in the frameworks that are necessary for providing strong research-based degree programmes.
The conference is being hosted today by Novo Nordisk from 12.30 to 16.30 at the company’s headquarters in Bagsværd. The debaters will include Danish Minister for Higher Education and Science Sofie Carsten Nielsen; Chair of the Government’s Expert Committee on Quality in Higher Education Jørgen Søndergaard; Rector of the University of Copenhagen Ralf Hemmingsen; and the political spokespersons for the Liberal Party of Denmark and the Danish Social Democrats.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018